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Summary
Inhibitors of dihydrofolate reductase (DHFR), an enzyme that catalyzes 5,6,7,8-tetra-
hydrofolate synthesis, have been used as antimicrobial as well as antimetabolite drugs for
a long time. Although structurally belonging to different classes, the majority of DHFR in-
hibitors contain 2,4-diamino substitution in pyrimidine ring. With the aim to introduce
pyrimido-pyrimidines as a novel class of bacterial DHFR (bDHFR) inhibitors, 42 com-
pounds belonging to that class have been tested and compared with 18 pteridines using
cell and enzyme models and docking studies. A few pyrimido-pyrimidine compounds
showed high potency (IC50£0.05 mM) and selectivity as inhibitors of bDHFR. These proper-
ties seem to be dependent on the stringent structure freedom and flexibility, based on the
specific combination of prerequisite structural motifs that enable pyrimido-pyrimidine
compounds to fit into bDHFR active site in a relatively specific manner. The presented re-
sults will help to set the basis for designing new small molecules, inhibitors of DHFR,
with interesting and potentially selective antibacterial properties.
Key words: dihydrofolate reductase, docking, inhibitors, pyrimido[4,5-d]pyrimidine-2,4-di-
amine, structure-activity relationship
Introduction
Dihydrofolate reductase or DHFR (EC 1.5.1.3.) cata-
lyzes NADPH-dependent reduction of 7,8-dihydrofolate
to 5,6,7,8-tetrahydrofolate (1,2), thus producing an im-
portant cofactor for a number of one carbon transfer re-
actions and is essential for the biosynthesis of purines,
pyrimidines and amino acids (3). Inhibition of DHFR ac-
tivity leads to a deficiency of thymidylate (dTMP), thus
causing inhibition of cell growth (4–6).
DHFR is an enzyme of a great importance in meta-
bolic pathways of the majority of both prokaryotic and
eukaryotic organisms. In contrast to microbial DHFRs,
mammalian DHFRs are highly conserved (7). Although
human and bacterial DHFR share only 26 % sequence
identity, overall 3D-structure of the proteins is rather
similar (7). The difference in the primary structure of
human DHFR and DHFRs from other species allows the
selective inhibition of the pathogen growth with ade-
quate inhibitors (6) without detrimental effects to the
human cells. On the other hand, some DHFR inhibitors
are used in therapy of non-infective human diseases like
psoriasis, inflammatory bowel disease, rheumatoid ar-
thritis and neoplastic diseases (3).
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The majority of DHFR inhibitors which are cur-
rently in use or being under investigation are derivates
of folic acid having 2,4-diamino substitution in pyrimi-
dine ring and structurally belong to different classes
(pyrimidines, pteridines, quinazolines, pyrido-pyrimi-
dines) (1,5) (Fig. 1). Reports on the interactions of DHFR
inhibitors with the active site of DHFR from different
species suggest that 2,4-diaminopyrimidine ring acquires
common binding interactions through the protonated N1
and 2-amino groups (1).
DHFR inhibitors are structurally divided in two
classes – classical antifolates, which are structural ana-
logues of folic acid bearing glutamate moiety in the dis-
tal part of the molecule, and non-classical antifolates,
which are lipophilic analogues of folic acid, lacking the
glutamate residue (3,5).
The aim of this study is to introduce pyrimido-py-
rimidines as a novel class of bacterial DHFR (bDHFR)
and in that way to set the basis for finding the inhibitor
with improved properties compared to the currently
available (trimethoprim, pyrimethamine, proguanil) or
investigated (iclaprim, brodimoprim) drugs. Here 60
compounds are presented, chosen from the in-house
compound library on the basis of the structural similari-
ties to the known non-classical DHFR inhibitors. They
were tested for potency and selectivity for bacterial (Esch-
erichia coli) and human DHFR.
Materials and Methods
Chemicals and enzymes
All chemicals were of analytical grade and, if not
stated otherwise, were purchased from Sigma (USA).
Human DHFR enzyme was purchased from Sigma (USA).
E. coli DHFR enzyme was kindly provided by J. J. Clem-
ent (Essential Therapeutics, Waltham, MA, USA).
Test compounds
The compounds structurally belonging either to py-
rimido[4,5-d]pyrimidine-2,4-diamine or 2,4-pteridinedia-
mine class were selected from the in-house library. In
pyrimido[4,5-d]pyrimidine class of compounds the bridge
area is composed of N-C moiety linked at the position 7,
while in pteridinediamine class, there is C-N moiety at
position 6. Purity of the compounds was determined to
be >95 % detected by HPLC/MS. All compounds were
initially dissolved in DMSO and subsequently diluted
with the culture medium to the final concentration prior
to use.
DHFR activity assay
The method used to determine DHFR activity was
modified according to the standard one (8). Briefly, the
enzyme activity was measured by monitoring the absor-
bance at 340 nm of the reaction mixture containing 20
nM DHFR, the tested compound (in the concentrations
ranging from 0.1 nM up to 100 mM), dihydrofolic acid
100 mM, NADPH 200 mM, and mercaptoethanol 5 mM in
Hepes buffer 100 mM, pH=7.0, at 37 °C. The concentra-
tions of the test compound required to reduce DHFR ac-
tivity by 50 % (IC50) were determined by semilogarith-
mic plots of the data yielding normal sigmoidal curves
using GraphPad Prism (v. 4.0 for Windows; GraphPad
Software Inc., San Diego, CA, USA).
Bacteria and cell line culture
E. coli IMPA and E. coli ET003 were kindly provided
by J. J. Clement (Essential Therapeutics, USA). E. coli
IMPA strain (imp4213::tn10) (9) is a highly permeable
strain of E. coli MG1655 (10). E. coli ET003 is highly per-
meable strain of E. coli LH18 strain, which is dhfr- strain
of E. coli MG1655. E. coli ET003 strain was made using
parent strain E. coli LH18 (11) and transduced using P1
lysate made on E. coli IMPA (imp4213::tn10). Bacteria
were grown in Luria Bertani (LB) medium, under the
standard conditions.
Human acute monocytic leukemia cell line THP-1
(ATTC TIB-202) was obtained from ATCC (Manassas,
VA, USA) and asynchronously grown (37 °C, 5 % CO2,
relative humidity 5 %) in RPMI 1640 medium supple-
mented with fetal bovine serum (10 %), penicillin G (100
U/mL), streptomycin-sulphate (100 mg/mL), amphoteri-
cin B (250 ng/mL) and plasmocin (2.5 mg/mL) (all pur-
chased from Gibco, Grand Island, NY, USA).
MIC determination
Microdilution MIC (minimal inhibitory concentra-
tion) determination was performed as recommended by
the National Committee for Clinical Laboratory Stan-
dards (NCCLS) (12). The growth inhibitory properties of
the test compounds were determined by a twofold serial
dilution method – for each compound the series of the
solutions whose concentrations differed by a factor of
two were prepared, to each solution a fixed amount of
the previously prepared test culture was added and the
mixture was incubated at 37 °C overnight. Antibacterial
activity of each compound was expressed as its MIC, i.e.
the lowest concentration that just inhibited bacterial
growth. Each concentration of the compounds was tested
in duplicate and in two independent experiments.
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Fig. 1. The majority of DHFR inhibitors are derivates of folic
acid. Core structures of the main classes of DHFR inhibitors con-
taining 2,4-diamino substituted pyrimidine ring are presented
Proliferation assay
Cell proliferation assay was performed using Cell-
Titer 96®AQueous One Solution Cell Proliferation Assay
(Promega) (13). THP-1 cells (5·104 cells/well) were placed
into 96-well flat bottom microtiter plate in a final vol-
ume of 100 mL of the medium containing test com-
pounds in the concentrations ranging from 0.1 nM up to
100 mM. After 72 hours of cultivation under standard
conditions, 20 mL of MTS were added into the medium
and cells were additionally incubated in the dark at 37
°C for the next 2 hours for colour development. The
absorbance was read at the wavelength of 490 nm using
the microplate reader Victor2-1420 Multilabel Counter
(PerkinElmer, Wellesley, MA, USA). Two independent
experiments were performed. The results were expressed
as EC50 values (the compound concentration that effi-
ciently inhibited cell growth by 50 %), determined with
GraphPad Prism (v. 4.0 for Windows; GraphPad Soft-
ware Inc., San Diego, CA, USA) from semilogarithmic
plots of the data yielding normal sigmoidal curves.
Docking study
Two-dimensional structures of all test compounds
were transformed into three-dimensional starting con-
formations for MOE (molecular operating environment;
Chemical Computing Group) using MMFF94 force field.
The protonation was adjusted to allow optimal interac-
tions with the protein active site. Crystal structures of
both, bDHFR cocrystalized with methotrexate (MTX)
(deposited in Protein Data Bank (PDB) as 1RA3) (14) and
hDHFR cocrystalized with LIH (6-([5-quinolylamino]-
methyl)-2,4-diamino-5-methylpyrido[2,3-d]pyrimidine),
a lypophilic antifolate (deposited in PDB as 1KMS) (15),
were used for molecular docking. GOLD (16) was also
used for molecular docking, as well as Goldscore fitness
function for ranking of the solutions. MOE 2006.08 and
GOLD 3.2 were used with default fitness function pa-
rameters and default GA options (population size 100,
no. of islands 5, no. of operations 100 000). Heavy atom
root mean square deviation (RMSD) between the crystal
and the best docked structure was 4.2 calculated by
smart_rms utility provided as part of GOLD package.
Molecular dynamics simulations
The 3D structures of human and bacterial DHFR
were taken from the PDB; 1KMS and 1RA3, respectively,
and their complexes with 24 were prepared by overlying
a low energy conformation of 24 with methotrexate in
1RA3 (14) and LIH in 1KMS (15). The complexes were
completed by the addition of all hydrogen atoms. Ac-
cording to the experimental conditions, all Asp and Glu
were negatively charged and all Lys and Arg were posi-
tively charged. Histidines were neutral and their proto-
nation site (either Nd or Ne) was determined according
to their neighborhood and probability of H-bond forma-
tion. For the purpose of complex simulation within the
program suite Amber, ligands were parameterized with
the gaff force field (17), and charges and missing param-
eters were determined using the modules Antechamber
and Parmcheck. Energy minimization and molecular dy-
namics (MD) simulations were performed with the San-
der modules of the Amber10 package (18) using the
ff03 force field (19). Simulations were performed in ex-
plicit solvent (TIP3P water type was used) (20) using pe-
riodic boundary conditions with a truncated octahedron
as a unit cell. The complex 1KMS-24 was neutral (i.e.
protein contained equal number of positively and nega-
tively charged amino acid residues, 25 of each), while to
assure neutrality of the 1RA3-24 system, 11 Na+ ions
were added. The long-range electrostatic interactions
were evaluated using Particle Mesh Ewald (PME) meth-
od (21) with cutoff radius of 11 Å for calculating the real
part contributions to electrostatic and van der Waals in-
teractions. The system was optimized before applying MD
simulations. Energy minimization was accomplished in
three steps: in the first two, the protein-backbone atoms
were restrained to the initial position with a harmonic
forces of 19 kcal/(mol·Å) and 1 kcal/(mol·Å), respec-
tively, and water molecules and substrate were relaxed.
In the third step, the whole system was unrestrained.
The time step used during MD simulation was 1 fs. The
equilibration was performed in two steps: heating and
density adjustment. The heating-up MD simulations
(temperature increasing from 0 to 300 K during 20 ps)
were performed at constant volume with the protein
backbone atoms restrained with a harmonic force of 9
kcal/(mol·Å). Density was adjusted for another 20 ps of
MD simulations at constant pressure (restraints as in the
previous step). MD production runs were carried out at
300 K for 100 ps. Temperature was controlled by Lan-
gevin dynamics with a collision frequency of 1 ps–1.
Results and Discussion
The substances tested in this study were selected
from the available in-house compound library on the basis
of their structural resemblance to the known non-classi-
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Table 1. Structures of the tested 2,4-pteridinediamine derivates
Compound no. R1 R2
1 H –
2 CH3 –
3 CH2CH3 –
4 CH2CH2CH3 –
5 CH2CHCH2 –
6 CH2CH2CH2CH3 –
7 CH(CH3)2 –
8 H 3 CHOHCH3
9 H 4 OCH2CH3
10 H 4 NH2
11 H 3 NO2
12 CH3 3 NO2
13 CH3 4 COOH
14 CH3 4 COOCH3
15 H 3,4 C3H4
16 H 2,3 C4H4
17 H 3,4 C4H4
18 H 2,3 C4H34Cl
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cal DHFR inhibitors. Structurally the substances belong
to two classes: the first one comprises compounds hav-
ing pteridine ring (Table 1), while the second one com-
prises those with pyrimido-pyrimidine ring (Table 2).
Some pteridine compounds are well-known DHFR in-
hibitors, while pyrimido-pyrimidines have not yet been
described in literature as DHFR inhibitors. This is why
different representatives of this structural class have
been chosen for this study, and then it was searched for
pteridine substances that were structurally similar to the
chosen pyrimido-pyrimidines. Different phenyl or naph-
thyl derivates were linked to these ring structures by a
bridge moiety. In pteridine class the bridge moiety (C-N)
was attached at position 6, while in pyrimido-pyrimi-
dines the bridge (N-C) was at position 7, since saturated
nitrogen atom was at position 6. Additionally, the major-
ity of pyrimido-pyrimidine derivates had both atoms in
the bridge area substituted, while C atom in the bridge
area of pteridine derivates was not substituted.
The efficacy and the specificity of the compounds as
inhibitors of DHFR were tested in inhibition assays using
bacterial (E. coli; bDHFR) and human (hDHFR) enzyme,
while their growth inhibition properties were determined
using highly permeable strain of E. coli and its dhfr
knockout isostrain, and THP-1 cell line, as an eukaryotic
model. The obtained results expressed as IC50 values
(mM) for the inhibition of the enzymes, as MIC values
(mg/mL) for bacterial growth inhibition and as EC50 values
(mM) for THP-1 proliferation inhibition are presented in
Table 3. In all assays, methotrexate (MTX), a potent in-
hibitor of both bDHFR (IC50=5 nM) and hDHFR (IC50=
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Table 2. The structures of the tested pyrimido[4,5-d]pyrimidine-2,4-diamine derivates
Compd. no. R1 R2 R3 Compd. no. R1 R2 R3
19 CH3 H – 50 CH3 CH3 4CH3
20 CH2CH3 H 4 CH3 51 CH2CH3 CH3 4CH3
21 CH3 CH3 – 52 CH2CHCH2CH2 CH3 4CH3
22 CH3 CH3 4CH2OH 53 CH2CHCH2CH2 CH3 4Cl
23 CH3 H 2,3 C4H4 54 CH3 CH3 2CH2CH3
24 CH3 CH3 2,3 C4H4 55 CH3 H 2OCH2CH3
25 CH3 CH2OH 2,3 C4H4 56 CH2CH2COOH H 2OCH2CH3
26 CH2CH3 CH3 2,3 C4H4
27 CH2CH3 CH3 3,4 C4H4
28 CH2CH2OH CH3 2,3 C4H4
29 CH2COOH CH3 2,3 C4H4
30 CH2CH2CH3 CH3 2,3 C4H4
31 CH2CHCH2 CH3 2,3 C4H4
32 CH2CH2COOH CH3 2,3 C4H4
33 CH2CH2NH2 CH3 2,3 C4H4
34 CHCH2CH2 CH3 3,4 C4H4
35 CH2CHCH2CH2 CH3 2,3 C4H4 Compd. no. R1 R2
36 CH2CH2CH2CH3 CH3 2,3 C4H4 57 CH3 CH3
37 CH2CH2CH2COOH CH3 2,3 C4H4 58 CH2CH3 CH3
38 CH2CH2CH2CH2CH3 CH3 2,3 C4H4 59 CH2CHCH2CH2 CH3
39 CH2CH2CH2CH2NH2 CH3 2,3 C4H4
40 CH2CH2CH2CH2CH2NH2 CH3 2,3 C4H4
41 CH2CH2OCH2CH3 CH3 2,3 C4H4
42 CH2CH2OCH2CH2CH3 CH3 2,3 C4H4
43 CH2CH2OCH2CH2OH CH3 2,3 C4H4
44 CH2CH2CH2OCH2CH3 CH3 2,3 C4H4
45 CH2(CH2)2OCH2CH(CH3)2 CH3 2,3 C4H4
46 CH2C6H5 CH3 2,3 C4H4
47 CH2CH2C6H9 CH3 2,3 C4H4
48 CH2CH2C6H4F CH3 2,3 C4H4 Compd. no. R1 R2
49 CH2CH2CH2C3N2H2CH3 CH3 2,3 C4H4 60 CH3 CH3
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=1 nM) that inhibits only the growth of eukaryotic cell
(EC50=10 nM), and trimethoprim (TMP), a selective in-
hibitor of bacterial enzyme (IC50=10 nM) and bacterial
growth (MIC<0.125 mg/mL), were used as standard com-
pounds (Fig. 2).
The main structural differences among the com-
pounds within pteridine class arose from the moieties
attached to the nitrogen atom (N10) in the bridge area,
which were designated as R1, and the moieties attached
to phenyl linked to the nitrogen atom (N10), which were
designated as R2. Structurally the simplest compound
(1) within this class, bearing hydrogen as R1, showed
IC50 values in low micromolar range, 2.2 and 4.6 mM for
bDHFR and hDHFR, respectively. Introduction of meth-
yl group (2) instead of hydrogen as R1 increased anti-
bacterial potency of the compound four times, while the
extension of the moiety up to three carbon atoms (4),
caused an increase up to 20 times (IC50 0.15 mM and
MIC 0.125 mg/mL), which implies an enhancement of
the interactions of R1 groups with atoms in the active
site of bDHFR. However, further elongation of R1 moi-
ety (6) resulted in fourfold decrease of antibacterial ac-
tivity. These data suggest that the optimal number of
carbon atom units at this position is three or less. It was
previously shown that alkylation of N10 in pyrido-py-
rimidines (22,23) causes tenfold increase of their inhibi-
tory effects toward hDHFR and it was suggested that
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Table 3. The experimental results of the tested compounds (expressed as IC50, MIC and EC50 values)
Compd.
no.
bDHFR E. coli IMPA hDHFR THP-1 Select.
ratio
Compd.
no.
bDHFR E. coli IMPA hDHFR THP-1 Select.
ratioIC50 /mM MIC/(mg/mL) IC50 /mM EC50 /mM IC50 /mM MIC/(mg/mL) IC50 /mM EC50 /mM
1 2.2 4 4.6 23.3 2.09 32 0.93 >64 22 >100 23.66
2 n/a 1 n/a n/a n/a 33 2 2 >100 >100 –
3 0.11 0.5 n/a n/a n/a 34 4 4 15 13.7 3.33
4 0.15 0.125 1.6 1.6 10.67 35 0.6 0.5 8 10.3 13.33
5 0.15 0.125 2.0 6.2 13.33 36 1.84 2 4 39.6 2.17
6 0.6 0.5 1.7 2.6 2.83 37 2.73 >64 19.1 87.6 7.00
7 0.88 0.5 0.8 3.1 0.91 38 1.85 2 9 12.9 4.86
8 19 >64 >100 74.1 0.26 39 4.8 8 2.8 93 0.58
9 14 32 16 31.1 1.14 40 3 4 3.9 36.5 1.30
10 >100 >64 14 >100 – 41 1 1 4.9 32.6 4.90
11 n/a 2 n/a n/a n/a 42 3.3 4 29.4 19.1 8.91
12 n/a 0.125 n/a n/a n/a 43 1.7 2 10.1 28.7 5.94
13 0.2 64 n/a >100 n/a 44 3.5 4 32.6 32.6 9.31
14 2.2 2 0.3 19.1 0.15 45 3.4 4 34 12.7 10.00
15 >100 >64 n/a 35.6 n/a 46 0.88 1 13 14.4 14.77
16 11 16 0.5 32 0.05 47 2.5 2 7.8 12.7 3.12
17 48 64 21 >100 0.44 48 1.03 0.5 12.5 14.4 12.14
18 0.6 0.5 0.5 2.7 0.83 49 0.8 1 12.4 34.9 15.50
19 35.7 >64 82 >100 2.30 50 0.055 0.125 0.85 6 15.45
20 21.4 >64 n/a n/a n/a 51 0.21 0.25 1 5.2 4.76
21 11.2 16 9 >100 0.80 52 3.5 4 12.5 11.6 3.57
22 6.8 16 90.5 >100 0.08 53 2.2 2 12.5 8.1 5.68
23 3.5 4 9 33.8 2.57 54 3 8 27.8 5.4 9.27
24 0.016 0.125 16 22 1000.00 55 1.1 0.5 0.98 3.4 0.89
25 76 >64 14.1 108 0.19 56 8.3 >64 13.6 >100 1.64
26 0.2 0.25 17 11.6 85.00 57 0.05 0.125 2 15.9 40.00
27 3.2 4 33 22.9 10.31 58 0.15 0.125 2 5.7 13.33
28 0.3 0.25 13.3 18.5 44.33 59 0.27 0.25 1 5.2 3.70
29 21 >64 59.2 >100 2.82 60 0.7 0.5 8.8 33.4 12.57
30 0.96 0.5 15 18 15.63 MTX 0.005 >64 0.001 0.01 0.20
31 0.4 0.5 15 13.7 37.50 TMP 0.010 0.125 >100 >100 –
n/a – data not available
a) b)
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Fig. 2. Structures of: a) methotrexate (MTX) and b) trimethoprim (TMP)
N10 substitutions serve to partially restrain the confor-
mational flexibility, thus probably providing additional
interactions with the enzyme. However, according to an-
other hypothesis, N10 alkylation has little or no effect
on hDHFR inhibition, but affects transport of the com-
pounds into the cells (24). The modifications of phenyl
group at N10 position in pteridine class caused different
effects, e.g. the attachment of amino group (10) com-
pletely abolished antibacterial activity, while the intro-
duction of nitro group (11, 12) caused slight increase of
the activity (2- to 8-fold) compared to the compound
with just phenyl moiety (1, 2). These data suggest the
importance of electron-withdrawing group at this posi-
tion, probably due to the interactions with amino acid
residues in the active site of bDHFR enzyme. On the
other hand, the attachment of carboxyl group (13) did
not affect bDHFR inhibition ability, but it resulted in the
loss of antibacterial activity. Esterification of this acidic
group (14) led to 10 times reduced bDHFR inhibition,
but interestingly, antibacterial property was restored.
Since similar effect was also observed in THP-1 cells,
these findings suggest the importance of negatively
charged group in disabling the entrance of the com-
pounds into the cell. The presence of phenyl group at-
tached to N10 (1) is favourable compared to a-linked
naphthyl (16) for the bDHFR inhibition (phenyl derivate
was 5 times more potent than naphthyl); however, the
effect was reversed in the case of hDHFR, where phenyl
derivate was 8 times less potent than the naphthyl one.
The beneficial effect of naphthyl vs. phenyl moiety for
hDHFR inhibition was also described for other structur-
ally related compounds (quinazolines (25), pyrido-pyri-
midines (26) or deazaaminopterin derivates (24)), which
is in accordance with the findings that hDHFR active
site is larger than the active site in the bacterial enzyme.
The positioning of naphthyl moiety seems to be of im-
portance since the b-naphthyl derivate (17) showed 5 and
40 times decrease of bDHFR and hDHFR activity, re-
spectively, when compared to the a-naphthyl one (16).
The importance of naphthyl moiety positioning was also
observed in the case of both, pyrido-pyrimidines (24–26)
and 2,4-diamino-8-deazafolate analogues.
To be able to compare the selectivity of the com-
pound for bacterial vs. human enzyme, the ratio of IC50
values of bDHFR and hDHFR was calculated. Within
pteridine class none of the test compounds showed sig-
nificant selectivity since the ratio was mainly between
0.1 and 10.
For all tested pteridine derivates, docking simula-
tions predicted the same binding mode for both bDHFR
and hDHFR as for methotrexate. The highest scored
compound (Table 4) for bDHFR activity was the one
with carboxyl moiety attached to phenyl group (13),
while structurally the simplest one in this class (1) had
the smallest scores for both bDHFR and hDHFR. Alkyl-
ation of N10 was recognized to be preferred for the inhi-
bition of both enzymes. However, the results of docking
studies did not correlate with IC50 for bDHFR and rec-
ognized neither different effects of phenyl and naphthyl
group attached to N10 nor the influence of naphthyl po-
sitioning on the inhibition of both enzymes.
Structural differences among the tested compounds
belonging to pyrimido-pyrimidine class arose from the
diversities of substituents on nitrogen atom at position 9
(N9) in the bridge area, designated as R1, on carbon
atom at position 10 (C10), designated as R2, and sub-
stituents positioned on phenyl or naphthyl moiety (at-
tached) at position C10, designated as R3 (Table 2). Few
compounds bearing cyclic moieties different than phe-
nyl or naphthyl at C10, chosen in order to estimate the
importance of specific cyclic moiety at that particular
position, were also tested. Among the tested pyrimido-
-pyrimidines, the only compound bearing hydrogen as
R3 on the phenyl moiety (21), which showed moderate
inhibition of both bDHFR (11 mM) and hDHFR (9 mM),
had methyl groups as both R1 and R2, while the com-
pound lacking methyl moiety at the position C10 (19)
showed higher IC50 for both bDHFR (35.7 mM) and
hDHFR (82 mM). Similar effects were also observed in
the case of pyrido-pyrimidine DHFR inhibitors, where
methylation at the position N9 caused 15–40 times in-
crease of hDHFR inhibition (26). Taken together, these
data suggest the importance of small groups as substitu-
ents on the atoms in the bridge moiety of these com-
pounds for their activity as inhibitors of DHFR.
The compounds bearing naphthyl instead of phenyl
moiety showed strong inhibition of bDHFR (10 to 1000
times more active compared to those with phenyl group),
and interestingly, the most active one (24) also had me-
thyl groups as both R1 and R2, showing bDHFR inhibi-
tion comparable to both trimethoprim and methotrexate
(IC50=0.016 mM). Since it exhibited moderate hDHFR in-
hibition (IC50=24.7 mM), the selectivity ratio was calcu-
lated to be approx. 1000. Among all the tested com-
pounds, this one had the most potent antibacterial
properties (MIC=0.125 mg/mL). Like in pteridine class,
the positioning of naphthyl moiety seemed to be of im-
portance since 10 times decrease of IC50 values for
bDHFR and 2 to 3 times decrease of IC50 values for
hDHFR occurred when b (27) was shifted to a-position
(26). The elongation of R1 to up to four carbon atoms
(36) correlated with a decrease of inhibitory effects for
bDHFR (IC50 dropped from 0.016 to 2 mM). However,
further elongation did not cause additional change of
bDHFR inhibition and it seems that N9 substitution may
tolerate even larger groups like phenyl (46) or phenyl
derivates, without affecting activity of the compound. In
general, hDHFR inhibition was not very dependent on
the size of R1 moiety. The introduction of carboxyl
group as part of R1 (32, 37) did not affect bDHFR inhibi-
tion, but at the same time it caused the loss of antibacte-
rial activity. This phenomenon was independent of the
length of alkyl chain and it suggested that the presence
of negative charge has no influence on enzyme activity
but strongly influences the entrance of the compounds
into bacterial cell. Similar effect was also observed in the
case of hDHFR and THP-1 growth inhibition.
Growth inhibition of E. coli lacking DHFR (ET003
strain, dhfr–) was induced with the compounds bearing
two or three carbon moieties as R1 and to a smaller ex-
tent in the case of four carbon moieties (Table 5). The
cyclopropyl moiety as part of R1 seemed to be prerequi-
site for non-bDHFR antibacterial activity since 5 differ-
ent compounds (34, 35, 52, 53, 59) bearing this moiety
showed antibacterial activity for the strain lacking DHFR.
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All this suggests that size and spatial positioning of R1
substituents might be important for achieving interac-
tions with some targets other than DHFR or for mecha-
nisms of unspecified toxicity.
The presence of cyclic structures (57, 58, 59, 60) sim-
ilar to naphthyl moiety at position C10 caused no signif-
icant change of inhibitory properties of the compounds,
suggesting the importance of the moiety size at this po-
sition. On the other hand, introduction of various sub-
stituents on naphthyl moiety resulted in different effects
depending on substituent positioning and character. For
some more general conclusion, more compounds with
minimal structural differences on naphthyl moiety should
be tested.
Within pyrimido-pyrimidine class, 6 compounds
(24, 26, 28, 31, 32, 57) with high selectivity ratio were
recognized. In general, the selectivity was primarily due
to a high potency of the compounds to inhibit bDHFR
activity, while the ability to inhibit hDHFR was not in-
fluenced significantly. These compounds share some
structural similarities in having groups up to three at-
oms as R1, methyl moiety as R2 and naphthyl (or ben-
zo(b)thiophenyl – 57) attached to C10. Even a smallest
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Table 5. Minimal inhibitory concentration (MIC) values of the
chosen pyrimido-pyrimidines for wild type E. coli IMPA and its
dhfr knockout isostrain (dhfr–)
Compd.
no.
MIC/(mg/mL)
E. coli IMPA E. coli dhfr–
26 0.25 16
27 4 16
30 0.5 16
31 0.5 16
33 2 2
34 4 4
35 0.5 8
36 2 16
40 4 16
51 0.25 16
52 4 8
53 2 4
54 8 8
58 0.125 16
59 0.25 8
Table 4. Docking scores of the tested compounds for bDHFR and hDHFR compared to the IC50 values
Compd.
no.
bDHFR hDHFR Compd.
no.
bDHFR hDHFR
IC50/mM Dock. scores IC50/mM Dock. scores IC50/mM Dock. scores IC50/mM Dock. scores
1 2.2 54.9 4.6 65.16 32 0.93 69.54 22 82.09
2 n/a 68.29 n/a 81.3 33 2 68.91 >100 70.9
3 0.11 67.99 n/a 83.36 34 4 58.38 15 76.10
4 0.15 69.95 1.6 80.78 35 0.6 63.03 8 72.09
5 0.15 61.69 2.0 72.21 36 1.84 69.23 4 67.85
6 0.6 74.8 1.7 85.06 37 2.73 70.16 19.1 86.20
7 0.88 69.38 0.8 80.49 38 1.85 68.34 9 69.97
8 19 73.98 >100 77.79 39 4.8 71.88 2.8 73.87
9 14 69.41 16 76.5 40 3 70.39 3.9 69.27
10 >100 65 14 77.26 41 1 71.9 4.9 72.94
11 n/a 58.31 n/a 67.66 42 3.3 74.94 29.4 72.64
12 n/a 71.12 n/a 75.82 43 1.7 70.96 10.1 70.89
13 0.2 76.32 n/a 82.77 44 3.5 57.34 32.6 75.09
14 2.2 71.21 0.3 85.36 45 3.4 74 34 70.01
15 >100 60.57 n/a 70.87 46 0.88 65.08 13 76.87
16 11 57.46 0.5 69.04 47 2.5 75.75 7.8 76.48
17 48 62.02 21 73.18 48 1.03 80.87 12.5 85.01
18 0.6 59.14 0.5 74.53 49 0.8 83.19 12.4 81.03
19 35.7 62.84 82 66.17 50 0.055 61.74 0.85 73.4
20 21.4 52.12 n/a 63.79 51 0.21 64.62 1 68.5
21 11.2 57.69 9 65.94 52 3.5 71.96 12.5 73.97
22 6.8 67.98 90.5 68.48 53 2.2 68.86 12.5 75.79
23 3.5 57.15 9 69.78 54 3 58.43 27.8 70.52
24 0.016 58.92 16 68.65 55 1.1 67.02 0.98 81.82
25 76 66.52 14.1 69.87 56 8.3 69.35 13.6 84.01
26 0.2 55.2 17 69.65 57 0.05 59.9 2 78.45
27 3.2 56.61 33 71.31 58 0.15 69.8 2 74.6
28 0.3 68.54 13.3 65.34 59 0.27 75.04 1 80.27
29 21 71.43 59.2 85.22 60 0.7 63.13 8.8 64.51
30 0.96 61.78 15 74.08 MTX 0.005 95.88 0.001 109.78
31 0.4 71.7 15 74.36 TMP 0.010 >100
n/a – data not available
modification of these structural motifs led to a decrease
of bDHFR inhibition and consequently to the loss of se-
lectivity. Similar effect was observed when any of dis-
criminating motifs was missing, so it seems that high se-
lectivity is strongly related to relative narrow structural
motif identity.
The results of docking study (Table 4) were com-
pared to the compound structures and some relations
with the compound activities were observed. Docking
scores for both enzymes were higher for compounds
with bigger group attached to N9 position. In the case of
both DHFRs, but especially of hDHFR, the presence of
carboxyl group (32, 37) correlated with higher docking
values, suggesting the importance of negatively charged
groups. However, docking results did not reflect the in-
fluence of N9 methylation on the activity, the differences
that arose from the presence of phenyl vs. naphthyl moi-
ety attached to the position 10, as well as the effects of
naphthyl moiety positioning. It seems that for both
bDHFR and hDHFR the docking scoring did not have
predictive impact, since the corresponding scores were
not in significant correlation with the results of in vitro
study (IC50).
In order to rationalize reasons for high potency and
remarkable selectivity of compound 24 towards bDHFR
inhibition, the bDHFR-24 and hDHFR-24 complexes were
subjected to molecular dynamics (MD) simulations. For
this purpose the energy-minimized conformation of 24
was overlaid with methotrexate in the active site of
bDHFR, with LIH in the active site of hDHFR (Fig. 3)
(see Methods) and the complexes were solvated, neu-
tralized and relaxed. During MD simulations, hydrogen
bonds, either direct or water-mediated, between the
compound 24 and D27, I5, I94 and Y100 in the active
site of bDHFR were formed (Fig. 4), which are the same
amino acid residues as those that interact with metho-
trexate in the crystal structure (1RA3). Interaction between
24 and hDHFR was established through the H-bonds with
E30, I7 and L22, i.e. with some of the amino acid resi-
dues LIH interacts as well. Although MD simulations did
not show substantial difference between 24 bindings to
the active site of the two enzymes, it revealed slightly
larger number of H-bonds formed between 24 and bDHFR
than between 24 and hDHFR. However, it should be
stressed that the simulations were quite short.
hDHFR is a neutral molecule at physiological condi-
tions unlike highly negatively charged bDHFR and it
might be possible that favourable electrostatic forces are
one of the reasons for high affinity of compound 24 to-
wards bDHFR. Further on, the binding site entrance is
wider in bDHFR than in hDHFR, enabling easier accom-
modation of 24, especially the bulky naphthyl moiety,
into the bDHFR binding site than into that of hDHFR
and its binding in a specific way. Nevertheless, further
studies are needed for understanding the mechanism re-
sponsible for high activity and selectivity of this com-
pound.
Conclusions
Compounds with pyrimido-pyrimidine structure as
a novel class of DHFR inhibitors are proposed here. Some
of them have shown promising behaviour in bDHFR in-
hibition and their unique and distinctive structural
preferences could be a base for selectivity towards inhi-
bition of bacterial vs. human enzyme.
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Fig. 3. Overlay of: a) compound 24 (green/blue) with methotre-
xate (yellow) in the bDHFR active site; b) compound 24 (green/
blue) with LIH (yellow) in the hDHFR active site
Fig. 4. Some of the hydrogen bonds between the compound 24
and bDHFR formed during 100 ps of MD simulation at room
temperature. The substrate is shown as stick representation, the
water molecules as ball and stick representation, and the prote-
in amino acid residues as lines, with the amino acid residues
interacting with the compound 24 by direct hydrogen bonds
slightly highlighted. For the purpose of clarity only hydrogen
atoms in water molecules are shown
Screening results suggest a high importance of the
group size linked to the atoms in the bridge area. The
pteridine class of the compounds favours up to three-
-atom group linked to nitrogen atom in the bridge moi-
ety, while pyrimido-pyrimidines prefer just methyl group
for bDHFR inhibition. Furthermore, in the case of pyri-
mido-pyrimidines, naphthyl moiety linked by the bridge
area seems to be preferred over phenyl moiety for
bDHFR inhibition, which is opposite to the findings for
the compounds belonging to other structurally similar
classes. The negatively charged group seems to be of a
great importance for the entrance of the compounds be-
longing to both tested classes into the cell.
High selectivity of a few pyrimido-pyrimidines oc-
curs due to a higher potency of bDHFR inhibition with-
out effects on hDHFR inhibition. It seems that these few
compounds might have the stringent structure freedom
and flexibility, based on the specific combination of pre-
requisite structural motifs that enables them to fit into
bDHFR active site in relatively specific manner. The ac-
tive site of hDHFR being larger than the one of bDHFR
may not have stringency to accommodate these struc-
tures, so it may not ’recognize’ this unique and specific
structural motif in a manner like bDHFR active site
does. As a consequence, a few pyrimido-pyrimidine
compounds, carrying specific combination of substitu-
ents, exhibit stronger bDHFR inhibition and conse-
quently higher selectivity ratio.
Virtual screening of the compounds with described
properties may be inconclusive in some cases; however,
together with the results of experimental studies may
provide better understanding of the inhibition process.
Presented results will help to set the basis for designing
new small molecules, inhibitors of DHFR, with interest-
ing and potentially selective antibacterial properties.
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